Pfizer (PFE) Cost of Revenue (2009 - 2026)

Pfizer (PFE) has 18 years of Cost of Revenue data on file, last reported at $3.5 billion in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $3.5 billion, up 24.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.8 billion (up 13.41% YoY), and the FY2025 annual result was $16.1 billion, down 9.99% from the prior year.
• Cost of Revenue slipped to $3.5 billion in Q1 2026 per PFE's latest filing, from $5.3 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $10.0 billion in Q2 2022 and troughed at $2.8 billion in Q1 2025.
• A 5-year average of $5.4 billion and a median of $4.9 billion in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue jumped 140.17% in 2022, then sank 62.57% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $6.1 billion in 2022, then grew by 24.74% to $7.6 billion in 2023, then sank by 30.41% to $5.3 billion in 2024, then advanced by 0.17% to $5.3 billion in 2025, then plunged by 32.7% to $3.5 billion in 2026.
• Business Quant data shows PFE's Cost of Revenue at $3.5 billion in Q1 2026, $5.3 billion in Q4 2025, and $4.2 billion in Q3 2025.